
The role of hypofractionated radiotherapy (HFRT) in advanced breast cancer beyond symptom palliation remains underexplored. This study evaluated the efficacy, safety, and prognostic factors of local HFRT combined with systemic therapy, with exploratory tissue-based genomic profiling. This retrospective cohort included 67 advanced breast cancer patients who received HFRT (≥ 5 Gy/fraction, ≤ 10 fractions) to metastatic lesions between 2021 and 2026. Objective response rate (ORR), progression-free survival (PFS), time to next systemic therapy (TTNT), overall survival (OS), and adverse events (AEs) were assessed. Subgroup analyses were performed, and tumor sequencing was performed in 19 patients for somatic mutation analysis. The local ORR was 62.7
Ki67 is an established biomarker in breast tumors but so far, its role in endometrial cancer biology has not been studied. Therefore, the aim of the current study is to evaluate the association of Ki67 with molecular subgroups, ER status, and FIGO staging. Patients with endometrial cancer were retrospectively included. Ki67 expression was immunohistochemically assessed as the percentage of positive tumor nuclei and categorized as < 10
Abstract Purpose Sex and age have an impact on efficacy and toxicity of chemotherapy (ctx) in patients (pts) with esophagogastric adenocarcinoma (EGA). However, data are limited, as clinical trials frequently do not report sex-specific differences and older pts are often underrepresented. Methods MATEO is an international randomized trial, confirming non-inferiority of S-1 maintenance therapy compared to continued platinum-based ctx in pts with advanced EGA without disease progression after 3 months of ctx. Toxicity pattern favored S-1 monotherapy. We conducted a post hoc exploratory analysis to assess the impact of sex and age on treatment outcomes. Results In the per-protocol population, 112 pts (72.7%) were male and 42 (27.3%) were female. 37.7% of pts were ≥ 70 years. Female pts more often had distal stomach tumors (64.3%), while male pts had more esophagogastric junction tumors (76.7%). In a pooled analysis, female pts showed significantly longer progression-free survival (PFS) (median 9.9 vs. 4.3 months, HR 0.56 [95% CI 0.38–0.83], log-rank: p = 0.0033), and overall survival (OS) (median 14.4 vs. 12.2 months, HR 0.65 [95% CI 0.44–0.97], log-rank: p = 0.0348). No age-related differences in PFS and OS were observed between pts ≥ 70 years and < 70 years. In multivariate analyses, female sex, but not younger age, was associated with a trend towards improved OS. No significant sex- or age-specific differences in terms of toxicity were observed. Conclusion Primary tumor location differed by sex. A trend for superior outcome in female pts was observed, whereas age did not have a significant impact on outcome.
Abstract Purpose Desmoplastic small round cell tumors (DSRCT) are exceptionally rare and aggressive sarcomas with limited therapeutic options and scarce clinical evidence. We aimed to characterize the clinical course and treatment of patients with molecularly confirmed DSRCT and to investigate HER2 expression as a potential therapeutic target, including real-world experience with trastuzumab deruxtecan (T-DXd). Methods We retrospectively analyzed patients with DSRCT treated at our specialized and certified sarcoma center. Diagnosis was confirmed by detection of the pathognomonic EWSR1::WT1 fusion. Clinical characteristics, treatment strategies, surgical outcomes, HER2 immunohistochemistry (IHC), and fluorescence in situ hybridization (FISH) results were assessed. Clinical outcomes of patients receiving T-DXd were reviewed. Results Eleven patients were identified (median age 22 years, range 5–63; 81.8% male). HER2 IHC was 0 in three patients (27.3%), 1 + in three (27.3%), and 2 + in five (45.5%); none showed 3 + expression, and all tumors were FISH-negative. Two extensively pretreated patients with HER2 IHC 2+/FISH-negative tumors received off-label treatment with T-DXd and demonstrated initial radiological responses. One patient experienced subsequent progression and died, whereas the second maintained disease control after more than 10 cycles despite chronic dialysis and without substantial additional toxicity. Conclusions This molecularly confirmed cohort highlights the aggressive clinical course and substantial unmet therapeutic need in DSRCT. HER2 protein expression was observed in a considerable proportion of tumors despite the absence of HER2 amplification. Responses to T-DXd in two HER2 IHC 2+/FISH-negative patients provide a hypothesis-generating clinical signal supporting further investigation of HER2-directed antibody–drug conjugates in DSRCT.
The biomedical innovation landscape is increasingly shaped by high-growth startups, particularly “unicorns”—privately held companies valued at over 1 billion. While these entities generate significant economic value and drive digitalization and novel therapeutic development in oncology, their creation and integration into the research ecosystem remain unevenly distributed globally. Notably, Europe lacked a single medical unicorn in oncology before 2026. This study investigates the geographical distribution, financing structures, and investment focus of global oncology unicorns to understand the factors behind their success. It further aims to explore the potential of these entities to contribute to oncology research funding and to identify the critical gaps in the European startup ecosystem that prevent their emergence. We identified 21 oncology unicorns from the CB Insights database with business models clearly linked to oncology. Data on company valuation, financing stages (early, expansion, later), geographical origin, investor composition, and cumulative investment were analyzed. The 21 oncology unicorns represent a cumulative market valuation exceeding50 billion. Geographically, 18 (86